SQZ Biotechnologies Return on Investment 2020-2022 | SQZ

Current and historical return on investment (ROI) values for SQZ Biotechnologies (SQZ) over the last 10 years.
SQZ Biotechnologies ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-12-31 $-0.08B inf%
2022-09-30 $-0.08B inf%
2022-06-30 $-0.08B inf%
2022-03-31 $-0.07B inf%
2021-12-31 $-0.07B inf%
2021-09-30 $-0.07B inf%
2021-06-30 $-0.06B inf%
2021-03-31 $-0.06B inf%
2020-12-31 $-0.05B inf%
2020-06-30 $-0.03B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.018B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.233B 9.43
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.461B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.529B 0.00
Arcus Biosciences (RCUS) United States $1.165B 0.00
Biohaven (BHVN) United States $0.882B 0.00
Emergent Biosolutions (EBS) United States $0.391B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.153B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
Gelesis Holdings (GLS) United States $0.011B 0.00